ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - erythromycin as stearate - טבליה - erythromycin as stearate 500 mg - erythromycin - erythromycin - treatment of the following infections when caused by susceptible organisms: upper and lower respiratory tract infections. skin and soft tissue infections. conjunctivitis of the newborn caused by chlamydia trachomatis. urogenital infections caused by chlamydia trachomatis. venereal diseases (as an alternative regimen to penicillins and tetracyclines). intestinal amebiasis. legionnaires' disease. long-term prophylaxis in rheumatic fever. short-term prophylaxis against bacterial endocarditis in patients hypersensitive to penicillin who have congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures and surgical procedures of the upper respiratory tract. enteric infections caused by campylobacter jejuni.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - erythromycin as stearate - טבליה - erythromycin as stearate 250 mg - erythromycin - erythromycin - treatment of the following infections when caused by susceptible organisms: upper and lower respiratory tract infections. skin and soft tissue infections. conjunctivitis of the newborn caused by chlamydia trachomatis. urogenital infections caused by chlamydia trachomatis. venereal diseases (as an alternative regimen to penicillins and tetracyclines). intestinal amebiasis. legionnaires' disease. long-term prophylaxis in rheumatic fever. short-term prophlaxis against bacterial endocarditis in patients hypersensitive to penicillin who have congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures and surgical procedures of the upper respiratory tract. enteric infections caused by campylobacter jejuni.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - erythromycin as stearate - טבליה - erythromycin as stearate 250 mg - erythromycin - erythromycin - treatment of the following infections when caused by susceptible organisms: upper and lower respiratory tract infections. skin and soft tissue infections. conjunctivitis of the newborn caused by chlamydia trachomatis. urogenital infections caused by chlamydia trachomatis. venereal diseases (as an alternative regimen to penicillins and tetracyclines). intestinal amebiasis. legionnaires' disease. long-term prophylaxis in rheumatic fever. short-term prophlaxis against bacterial endocarditis in patients hypersensitive to penicillin who have congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures and surgical procedures of the upper respiratory tract. enteric infections caused by campylobacter jejuni.

ישראל - עברית - Ministry of Health

sanofi israel ltd - metronidazole - טבליות מצופות פילם - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - rifabutin - קפסולות - rifabutin 150 mg - rifabutin - rifabutin - for the treatment of chronic tuberculosis where there is evidence of acid fast bacteria resistant to rifampicin or to two other alternative drugs. for the treatment of infections caused by mac or other atypical mycobacteria where there is evidence of resistant bacteria as above. for the treatment of infections caused by mac or other atypical mycobacteria in aids patients in all cases not subject to the above restrictions. for prevention of mac infections in aids patients whose cd4 counts lower or eqval to 200/mm3

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - אבקה להכנת תמיסה לאינפוזיה - aciclovir 250 mg/vial - aciclovir - aciclovir - for the treatment of herpes simplex infections and severe initial genital herpes in the non immunocompromised. for the prophylaxis of herpes simplex infections in immune-compromised patients. in the treatment of varicella zoster infections. for herpes simplex encephalitis. for the treatment of herpes simplex infection in the neonate and infant up to 3 months of age.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - תמיסה לאינפוזיה - zidovudine 200 mg / 20 ml - zidovudine - zidovudine - retrovir iv for infusion is indicated for the short term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immuno deficiency syndrome (aids) or aids related complex (arc) who are unable to take retrovir oral formulations.

ישראל - עברית - Ministry of Health

novartis israel ltd - nilotinib as monohydrate - קפסולות - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

ישראל - עברית - Ministry of Health

novartis israel ltd - nilotinib as hydrochloride monohydrate - קפסולות - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 4.5 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m